Global Nasal Decongestant Market Insights, Forecast to 2028

Nasal decongestant is a type of pharmaceutical drug that is used to relieve nasal congestion in the upper respiratory tract. The active ingredient in most decongestants is either pseudoephedrine or phenylephrine (the latter of which has disputed effectiveness).
Market Analysis and Insights: Global Nasal Decongestant Market
Due to the COVID-19 pandemic, the global Nasal Decongestant market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, Nasal Strips accounting for % of the Nasal Decongestant global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Asthma segment is altered to an % CAGR throughout this forecast period.
China Nasal Decongestant market size is valued at US$ million in 2021, while the US and Europe Nasal Decongestant are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Nasal Decongestant landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Nasal Decongestant include Abbott Laboratories, Glaxosmithkline, Cipla, Bayer, ADAPT Pharma, Patrick Parsons, Nidda Healthcare, Procter and Gamble and Rugby Laboratories. etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Nasal Decongestant Scope and Segment
Nasal Decongestant market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Nasal Decongestant market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Nasal Strips
Tablet
Spray
Capsule
Segment by Application
Asthma
Cold
Nasal Allergies
By Company
Abbott Laboratories
Glaxosmithkline
Cipla
Bayer
ADAPT Pharma
Patrick Parsons
Nidda Healthcare
Procter and Gamble
Rugby Laboratories
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE